Eric J. Cunningham is Foregen’s Chief Science Officer. He holds a Bachelor’s Degree in Biomedical Engineering, with a specialization in Cell & Tissue Engineering, from Illinois Institute of Technology’s Armour College of Engineering. He is currently completing a Master’s Degree in Chemical Engineering at Illinois Institute of Technology.
Tyler is a driven advocate for genital integrity and pursuing the goal of giving every man back the choice of a whole body. He has considerable international experience, working with people from a variety of countries. After graduating from North Central College with a degree in World Languages - Spanish, German and Chinese, he became a Fulbright Scholar to Germany, where he is currently in his second year.
Shingo Lavine is a successful entrepreneur, business leader and technologist. Shingo started his first company, Ethos.io, at age 19 while studying Computer Science at Brown University. Ethos was a blockchain company building a Universal Wallet that supported over 100 digital assets on top of a proprietary, high-performance blockchain abstraction architecture which today is used to power nearly $500 million in transactions and assets.
Mason is a long-time supporter of bodily autonomy, working to share vital information about male anatomy. He's thoroughly researched circumcision and the purposes of the human foreskin, which motivated him to aid in restoring hope to men around the globe. Since 2019, he has moderated an unofficial Foregen community, and now interns at Foregen's Department of Digital Development and IT. His primary goal is to utilize his skills to increase public attention and knowledge of Foregen by further developing the company's digital presence, especially the website.
As Senior Director, Matthew works closely with other members of the administration, advisors, and outside partners to address Foregen's unique challenges and lead its team of dedicated staff. Previously, he helped to establish Foregen's European financial network, co-authored Foregen's first published paper, and has spoken on behalf of the company to international groups, medical and pharmaceutical conglomerates, and members of the international media.